中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2015年
2期
10-12
,共3页
慢性阻塞性肺疾病急性加重期%雾化吸入%布地奈德%甲泼尼龙%地塞米松
慢性阻塞性肺疾病急性加重期%霧化吸入%佈地奈德%甲潑尼龍%地塞米鬆
만성조새성폐질병급성가중기%무화흡입%포지내덕%갑발니룡%지새미송
Acute exacerbation of chronic obstructive pulmonary disease%Inhalation aerosol%Budesonide%Methylprednisolone%Dexamethasone
目的：比较雾化吸入糖皮质激素激素与静脉使用不同糖皮质激素治疗中重度慢性阻塞性肺疾病急性加重期（AECOPD）患者的疗效及安全性。方法：将住院的84例中重度AECOPD患者随机分为雾化吸入布地奈德组、静脉滴注甲泼尼龙组和静脉滴注地塞米松组，观察三组患者治疗前及治疗后第7天呼吸困难评分、血气分析、肺功能及不良反应。结果：治疗后各组患者呼吸困难评分、肺功能及动脉血气分析指标较治疗前均有明显改善，其中三组肺功能治疗后比较差异有统计学意义（P<0.05），雾化吸入布地奈德组与静脉滴注甲泼尼龙组比较差异无统计学意义（P>0.05）。雾化吸入布地奈德组的不良反应明显少于静脉滴注甲泼尼龙组和地塞米松组。结论：糖皮质激素对中重度AECOPD有较好的近期疗效，雾化吸入布地奈德组与静脉滴注甲泼尼龙组的疗效相当，并优于静脉滴注地塞米松组，而且不良反应明显少于静脉使用糖皮质激素，雾化吸入布地奈德可作为糖皮质激素治疗中重度AECOPD的另一种更好的选择。
目的：比較霧化吸入糖皮質激素激素與靜脈使用不同糖皮質激素治療中重度慢性阻塞性肺疾病急性加重期（AECOPD）患者的療效及安全性。方法：將住院的84例中重度AECOPD患者隨機分為霧化吸入佈地奈德組、靜脈滴註甲潑尼龍組和靜脈滴註地塞米鬆組，觀察三組患者治療前及治療後第7天呼吸睏難評分、血氣分析、肺功能及不良反應。結果：治療後各組患者呼吸睏難評分、肺功能及動脈血氣分析指標較治療前均有明顯改善，其中三組肺功能治療後比較差異有統計學意義（P<0.05），霧化吸入佈地奈德組與靜脈滴註甲潑尼龍組比較差異無統計學意義（P>0.05）。霧化吸入佈地奈德組的不良反應明顯少于靜脈滴註甲潑尼龍組和地塞米鬆組。結論：糖皮質激素對中重度AECOPD有較好的近期療效，霧化吸入佈地奈德組與靜脈滴註甲潑尼龍組的療效相噹，併優于靜脈滴註地塞米鬆組，而且不良反應明顯少于靜脈使用糖皮質激素，霧化吸入佈地奈德可作為糖皮質激素治療中重度AECOPD的另一種更好的選擇。
목적：비교무화흡입당피질격소격소여정맥사용불동당피질격소치료중중도만성조새성폐질병급성가중기（AECOPD）환자적료효급안전성。방법：장주원적84례중중도AECOPD환자수궤분위무화흡입포지내덕조、정맥적주갑발니룡조화정맥적주지새미송조，관찰삼조환자치료전급치료후제7천호흡곤난평분、혈기분석、폐공능급불량반응。결과：치료후각조환자호흡곤난평분、폐공능급동맥혈기분석지표교치료전균유명현개선，기중삼조폐공능치료후비교차이유통계학의의（P<0.05），무화흡입포지내덕조여정맥적주갑발니룡조비교차이무통계학의의（P>0.05）。무화흡입포지내덕조적불량반응명현소우정맥적주갑발니룡조화지새미송조。결론：당피질격소대중중도AECOPD유교호적근기료효，무화흡입포지내덕조여정맥적주갑발니룡조적료효상당，병우우정맥적주지새미송조，이차불량반응명현소우정맥사용당피질격소，무화흡입포지내덕가작위당피질격소치료중중도AECOPD적령일충경호적선택。
Objective:To compare the effect and safety of budesonide inhalation aerosol with intravenous glucocorticoids in the treatment of the acute exacerbation of chronic obstructive pulmonary disease(AECOPD). Method: Totally 84 subjects with AECOPD were randomly divided into three groups. All patients were treated with budesonide inhalation aerosol, the intravenous methyl-prednisolone(IVM), and the intravenous dexamethasone. Three groups used 7 days therapy. The mMRC, blood gas analysis, pulmonary function and adverse reactions of three groups were observed.Result:The mMRC,blood gas analysis, and pulmonary function of three groups were significantly improved after treatment(P<0.05).The group of budesonide inhalation aerosol was no significantly improved compared to intravenous methyl-prednisolone(IVM)(P>0.05).The adverse reactions of budesonide inhalation aerosol group were significantly improved compared to intravenous methyl-prednisolone(IVM) group, and the intravenous dexamethasone group(P<0.05).Conclusion: The effect of Intravenous glucocorticoids treatment of the acute exacerbation of chronic obstructive pulmonary disease(AECOPD) is significant, there is no significant difference between budesonide inhalation aerosol group and intravenous methyl- prednisolone(IVM) group, but significantly improved than intravenous dexamethasone.At the same time,the adverse reactions of budesonide inhalation aerosol were less than intravenous glucocorticoids.So budesonide inhalation aerosol can be as another method to treat AECOPD,worthy of clinical application.
